

FOR IMMEDIATE RELEASE

Immunoxel to be presented at the 5th Congress of the International Union against Tuberculosis and Lung Disease

Sydney NSW, 27 May 2009 -- Zodiac Capital Limited (NSX: ZOD) is pleased to advise that Dr. Galyna Kutsyna will be presenting the efficacy and safety of Immunoxel in TB treatment through an "Adjunct Immunotherapy of XDR-TB" poster at the 5th Congress of the International Union against Tuberculosis and Lung Disease (The Union), European Region being held in Dubrovnik, Croatia between 27 and 30 May 2009.

The purpose of the Congress of the International Union against Tuberculosis and Lung Disease (The Union) is to provide an interdisciplinary forum where investigators involved in basic, applied, and clinical research worldwide can meet to review recent developments in all areas of TB research. The Conference covers topics of current interest and concern ranging from the design and synthesis of new potential drugs to current results from clinical trials. The meeting provides a truly interdisciplinary view of contemporary TB drug research that should be of interest to biologists and clinicians. For more information on the Conference please see: <http://www.depol.org/TheUnion2009/>

The presentation will summarize the recent treatment results evidenced in patients with XDR-TB, some of whom in addition to standard anti-TB therapy (ATT) received Immunoxel (Dzherelo), Svitank and Lisorm – all being phytopharmaceutical products that are subject to the recently announced and pending Joint Venture with Stirling Products Limited.

All seven patients who received adjunct immunotherapy improved clinically and radiologically and were discharged after 3.7 ± 0.8 months, with average/median time to mycobacterial sputum clearance 28/25 days. None of five patients on TB drugs alone improved after 9 months and one had died. Patients in immune intervention group gained 9.6 kg ($P=0.0001$) while those on ATT alone lost 1.4 kg. The levels of total bilirubin in Immunoxel group had decreased from 15.6 to 10.7 $\mu\text{mol/L}$. Similarly, the values of alanine transaminase (ALT) declined from abnormally high 42.6 IU/L to normal levels 22.0 IU/L ($P=0.23$). Patients on TB drugs alone had unchanged levels of bilirubin, but their ALT declined from 29.6 to 12.0 IU/L ($P=0.02$). The levels of hemoglobin in Immunoxel group rose from 104.1 to 118 g/L ($P=0.07$), whereas leukocyte counts descended to normal levels from 8.9 to 7.3×10^9 cells/L ($P=0.18$). Conversely, in patients on ATT alone, leukocyte counts rose from 8.7 to 13.8×10^9 cells/L ($P=0.21$), whereas hemoglobin declined to below normal levels from 116.4 to 96.6 g/L ($P=0.18$). These results show that immune-modulating interventions can favorably influence the efficacy of TB drugs. The difference

between two treatment outcomes was highly significant (Mantel Haenszel odds ratio=11; P=0.0009 at 95% CI). Thus, demonstrating that the Immunoxel and other supplementary adjunct phytopharmaceuticals are safe, dramatically shorten treatment duration, and can overcome drug resistance even in patients with XDR-TB.

Conventional TB chemotherapy success rates are inconsistent in patients with XDR-TB also known as Extremely Drug-Resistant TB. XDR-TB is defined as TB that is resistant to any fluoroquinolone, and at least one of three injectable second-line drugs (capreomycin, kanamycin, and amikacin), in addition to the two most commonly used drugs in the current first-line regimen, isoniazid and rifampin. Current XDR-TB treatment is extremely lengthy and complicated, with some strains virtually untreatable. XDR-TB is seen throughout the world but is most frequently seen in the countries of the former Soviet Union, Africa and Asia.

The US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) surveys indicated that in the worst-affected countries, 10 percent of MDR-TB cases were XDR-TB. The WHO estimates that there were almost half a million cases of MDR-TB worldwide. Research is being carried out urgently to better understand XDR-TB, and the WHO and others have mounted an intensified global response to this escalating incidence of resistance being evidenced worldwide.

The Ekomed Director, Mr. Volodymyr Pylypchuk commented: "We are very proud that our study has attracted the attention of world renowned TB experts and that consequently we were invited to present our data at this Conference. As long as TB is treated with a long, complex, decades-old drugs' regimen, XDR-TB will continue to remain a life-threatening disease with unmet needs. Immunomodulators, such as our Immunoxel product, can overcome any bacterial drug resistance since our compounds act through a totally new immune mechanism. Our phytochemicals are the first and only known products that can enhance the host's defense against mycobacterial infections. We can drastically shorten treatment duration and cure patients even with XDR-TB."

Immunoxel is one of 26 phytopharmaceutical (botanical) products being commercialised globally under a Zodiac Capital Limited License Agreement that, subject to approval at a meeting of Stirling Products Limited shareholders scheduled for 29 May 2009, the Company has agreed to joint venture with Stirling Products Limited.

CONTACT: For further detail or inquiry please contact:

Peter Squire +61 (0) 400 025 471 peter.squire@zodiaccap.com

Zodiac Capital Limited
Tel: +61 (0) 2 9299 9270